Oral fingolimod for relapsing-remitting multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
BACKGROUND Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis. METHODS We randomly assigned 281 patients to receive oral fingolimod, at a dose of 1.25 mg or 5.0 mg, or a placebo once daily, and we followed these patients for 6 months with magnetic resonance imaging (MRI) and clinical evaluations (core study, months 0 to ...
متن کاملSafety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
Introduction: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS. Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned to receive fingolimod 0.5 mg per day for 12 months. The number of D...
متن کاملOral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
BACKGROUND Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on imaging in a phase 2 study involving patients with multiple sclerosis. METHODS In this 12-month, double-blind, double-dummy study, we randomly assigned 1292 patients with relapsing-remitting multiple sclerosis who had a rece...
متن کاملOral laquinimod for treatment of relapsing-remitting multiple sclerosis.
Laquinimod is a novel oral immunomodulator developed as a disease-modifying drug for relapsing-remitting multiple sclerosis (RRMS). This molecule was developed following a structure-activity relationship program with Roquinimex. Laquinimod has shown a marked beneficial effect in acute, chronic progressive and chronic relapsing models of experimental autoimmune encephalomyelitis. It shifts the c...
متن کاملOral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis
BACKGROUND Recent data from animal models of multiple sclerosis (MS) and from a pilot study indicated a possible beneficial impact of statins on MS. METHODOLOGY/PRINCIPAL FINDINGS Safety, tolerability and effects on disease activity of atorvastatin given alone or in combination with interferon-beta (IFN-beta) were assessed in a phase II open-label baseline-to-treatment trial in relapsing-remi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Opinion on Pharmacotherapy
سال: 2010
ISSN: 1465-6566,1744-7666
DOI: 10.1517/14656566.2010.481671